The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Dapagliflozin plus calorie restriction beneficial for patients with overweight or obesity and type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback